Novel Prognostic Nomogram to Predict Progression-Free Survival of Patients with Hepatocellular Carcinoma After Transarterial Chemoembolization

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62(5):1187–1195. doi:10.1016/j.jhep.2015.02.010
   PubMed Web of Science ®Google Scholar
• Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164–1171. doi:10.1053/jhep.2002.33156
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi:10.1002/hep.29086
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet. 2009;373(9664):614–616. doi:10.1016/S0140-6736(09)60381-0
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Gonen M, Smith JJ, et al. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173–e180. doi:10.1016/S1470-2045(14)71116-7
   PubMed Web of Science ®Google Scholar
• Cho U, Park HS, Im SY, et al. Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer. PLoS One. 2018;13(7):e0200936. doi:10.1371/journal.pone.0200936
   PubMed Web of Science ®Google Scholar
• Ni JY, Fang ZT, Sun HL, et al. Nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation. Eur Radiol. 2020;30(4):2377–2390. doi:10.1007/s00330-019-06438-8
   PubMed Web of Science ®Google Scholar
• Hsu CY, Liu PH, Ho SY, et al. Using nomogram of the Barcelona clinic liver cancer system for treatment selection in patients with stage C hepatocellular carcinoma. BMC Cancer. 2018;18(1):289. doi:10.1186/s12885-018-4202-3
   PubMed Web of Science ®Google Scholar
• Shen J, He L, Li C, et al. Prognostic nomograms for patients with resectable hepatocelluar carcinoma incorporating systemic inflammation and tumor characteristics. Oncotarget. 2016;7(49):80783–80793. doi:10.18632/oncotarget.13038
   PubMedGoogle Scholar
• Feng LH, Dong H, Lau WY, et al. Novel microvascular invasion-based prognostic nomograms to predict survival outcomes in patients after R0 resection for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2017;143(2):293–303. doi:10.1007/s00432-016-2286-1
   PubMed Web of Science ®Google Scholar
• Takuma Y, Shota I, Miyatake H, et al. Nomograms to predict the disease-free survival and overall survival after radiofrequency ablation for Hepatocellular carcinoma. Intern Med. 2018;57(4):457–468. doi:10.2169/internalmedicine.9064-17
   PubMed Web of Science ®Google Scholar
• Berardi G, Morise Z, Sposito C, et al. Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis. J Hepatol. 2020;72(1):75–84. doi:10.1016/j.jhep.2019.08.032
   PubMed Web of Science ®Google Scholar
• Antkowiak M, Gabr A, Das A, et al. Prognostic role of albumin, bilirubin, and ALBI Scores: analysis of 1000 patients with hepatocellular carcinoma undergoing radioembolization. Cancers. 2019;11(6):879. doi:10.3390/cancers11060879
   PubMed Web of Science ®Google Scholar
• Zhou L, Wang SB, Chen SG, et al. Prognostic value of ALT, AST, and AAR in Hepatocellular carcinoma with B-type hepatitis-associated cirrhosis after radical hepatectomy. Clin Lab. 2018;64(10):1739–1747. doi:10.7754/Clin.Lab.2018.180532
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-The ALBI grade. J Clin Oncol. 2015;33(6):550–558. doi:10.1200/JCO.2014.57.9151
   PubMed Web of Science ®Google Scholar
• Toyoda H, Lai PB, O’Beirne J, et al. Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. Br J Canc. 2016;114(7):744–750. doi:10.1038/bjc.2016.33
   PubMed Web of Science ®Google Scholar
• Khalid MA, Achakzai IK, Hanif FM, et al. To determine the prognostic value of the albumin-bilirubin grade (ALBI) in patients underwent transarterial chemoembolization for unresectable hepatocellular carcinoma. Gastroenterol Hepatol Bed Bench. 2019;12(2):110–115.
   PubMedGoogle Scholar
• Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–1739. doi:10.1016/S0140-6736(02)08649-X
   PubMed Web of Science ®Google Scholar
• Xue TC, Xie XY, Zhang L, et al. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterol. 2013;13:60. doi:10.1186/1471-230X-13-60
   PubMed Web of Science ®Google Scholar
• Stotz M, Gerger A, Eisner F, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013;109(2):416–421. doi:10.1038/bjc.2013.332
   PubMed Web of Science ®Google Scholar
• Chang SK, Hlaing WW, Yu RQ, et al. Value of alpha-foetoprotein for screening of recurrence in hepatocellular carcinoma post resection. Singapore Med J. 2012;53(1):32–35.
   PubMed Web of Science ®Google Scholar
• Chen JG, Parkin DM, Chen QG, et al. Screening for liver cancer: results of a randomized controlled trial in Qidong, China. J Med Screen. 2003;10(4):204–209. doi:10.1258/096914103771773320
   PubMed Web of Science ®Google Scholar